News

Cardiff Oncology to Showcase Innovations at Upcoming Investor Events

Cardiff Oncology to Showcase Innovations at Upcoming Investor Events

Cardiff Oncology's Upcoming Investor Conferences

Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology firm, actively works on innovative therapies that target various types of cancer through PLK1 inhibition. In an exciting announcement, the company confirmed its management team will take part in three significant investor conferences coming up this September. These events present a fantastic opportunity for Cardiff to engage with investors, share insights about its promising therapies, and discuss its vision for transforming cancer treatment.

Wells Fargo 20th Annual Healthcare Conference

Event Details

The first event on the calendar is the Wells Fargo 20th Annual Healthcare Conference. This event is scheduled for September 5, 2025, and will feature one-on-one meetings with interested investors. Engaging in this format allows Cardiff Oncology to provide a tailored discussion around its innovative research and clinical advancements directly.

Morgan Stanley 23rd Annual Global Healthcare Conference

Connecting with Investors

Shortly after, on September 8, 2025, Cardiff will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. Also featuring one-on-one meetings, this conference provides an excellent platform for Cardiff Oncology to connect with global investors who are interested in the future of healthcare and biotechnology.

H.C. Wainwright 27th Annual Global Investment Conference

Mark Erlander's Presentation

The final event, the H.C. Wainwright 27th Annual Global Investment Conference, is set to occur on September 9, 2025. Notably, CEO Mark Erlander will present during a fireside chat and will also engage in one-on-one meetings with participants. This conference features a unique opportunity for the leadership team to articulate their cutting-edge research and development efforts in front of a captivated audience.

Innovations in Cancer Treatment

Cardiff Oncology is at the forefront of developing targeted cancer therapies, with its main asset being onvansertib, a PLK1 inhibitor. This compound aims to enhance the effectiveness of standard treatments for RAS-mutated metastatic colorectal cancer, as well as other significant cancer types like metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer. Such endeavors underline Cardiff's commitment not just to advance treatment options but also to improve clinical outcomes for patients facing treatment-resistant cancers.

The Company’s Broader Impact

As Cardiff Oncology continues to push the boundaries of cancer research, it remains focused on identifying and exploiting tumor vulnerabilities. The company's strategy seeks to deliver more effective treatment options, thereby addressing the challenges of treatment resistance. By leveraging innovative approaches, Cardiff is striving for superior clinical benefits compared to traditional therapies.

Engagement and Opportunities

Investors interested in following the H.C. Wainwright conference can register for the live webcast online. Additionally, a replay of the presentation will be accessible for those who wish to revisit the insights shared during the event. Engaging directly with the leaders of Cardiff Oncology allows investors to gain a profound understanding of the company’s direction and its significant contributions to cancer care.

Cardiff Oncology Contact Information

For any inquiries, potential investors and media can reach out to:

James Levine
CFO
858-952-7670
jlevine@cardiffoncology.com

Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Meghan Bianco
Taft Communications
609-544-5446
meghan.bianco@rfbinder.com

Frequently Asked Questions

What does Cardiff Oncology focus on?

Cardiff Oncology specializes in developing innovative therapies that target cancers using PLK1 inhibition.

When will Cardiff Oncology participate in investor conferences?

Cardiff will participate in three investor conferences in September 2025.

Who will present at the H.C. Wainwright conference?

CEO Mark Erlander will present at the H.C. Wainwright 27th Annual Global Investment Conference.

What is the company’s lead therapy?

The company’s lead asset is onvansertib, a PLK1 inhibitor aimed at enhancing existing cancer treatments.

How can I access the live webcast?

Interested parties can register for the H.C. Wainwright conference by visiting Cardiff Oncology’s website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 160

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 125

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 116

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 221

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 96

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 137

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 167

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 135

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 253

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 44

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

DICK'S Sporting Goods Achieves Record Sales in Q2 2025

Updated Category News Views 247

DICK'S Sporting Goods Achieves Strong Q2 Performance DICK'S Sporting Goods, Inc. (NYSE: DKS) has reported impressive results for the second quarter of the fiscal year, showcasing its ability to drive sales and enhance customer experience. The company delivered remarkable second quarter sales alongside a 5.0% growth in comparable sales, reflecting the effectiveness of its...

Continue Reading
Kratos Defense Stock Update: Growth Prospects Remain Bright

Updated Category News Views 267

Overview of Kratos Defense & Security Stock Performance Recently, Kratos Defense (NASDAQ: KTOS) has been a focal point for investors due to its fluctuating stock status. B.Riley analyzed Kratos Defense & Security and modified its recommendation from a Buy rating to a Neutral one. This change came despite the price target being raised from $24 to $26, indicating a complex...

Continue Reading
ASP Isotopes Inc. Class Action Lawsuit: Key Information for Investors

Updated Category News Views 172

Important Update for ASP Isotopes Inc. Investors Levi & Korsinsky, LLP is alerting all stakeholders involved with ASP Isotopes Inc. (NASDAQ: ASPI), regarding significant legal developments. Investors who have experienced losses from this entity should take note of the class action securities lawsuit currently in progress. Understanding the Class Action Lawsuit The ongoing...

Continue Reading
Pellera Technologies Celebrates Major Innovation Award at Summit

Updated Category News Views 145

Pellera Technologies Recognized at Cisco Partner Summit Pellera Technologies is thrilled to share its achievement of being named Innovation Partner of the Year for the Americas USA East Region at the recent Cisco Partner Summit. This accolade underscores Pellera's dedication to excellence, leadership, and innovative practices in the technology sector. Significance of the...

Continue Reading
Rocket Companies Transforms Homeownership with Major Merger

Updated Category News Views 282

Rocket Companies Acquires Mr. Cooper Group The acquisition marks a historic moment in the mortgage industry, as Rocket Companies (NYSE: RKT), a prominent homeownership platform, has successfully completed its $14.2 billion purchase of Mr. Cooper Group. This union stands as the largest independent mortgage transaction in history, strategically combining America's leading...

Continue Reading